Expert Interview
Delving into the recent data from ASH2022 on Affimed's innate cell engager AFM13 for treating CD30-positive lymphoma
Ticker(s): AFMDInstitution: City of Hope
- Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
- Manages 150 patients with lymphoma (1/2 are CD30+) and 10 patients with relapsed refractory CLL.
- Specializes in the treatment of lymphomas as well as stem cell transplantation and cellular immunotherapy; participates in multiple clinical trials in the areas of lymphoma, transplant and immunotherapy.
Please describe your clinical practice; how many patients with solid tumors do you treat on a yearly basis, what percent of your patients could benefit from upcoming novel drugs ? How much need is there for a tetravalent, bispecific innate cell engager such as AFM24?
Could you please explain to us the mechanism of action behind the drug’s ability to bind to CD16A on innate immune cells and EGFR, and how that translates into better patient outcomes? Where do you see the benefits of this approach vs standard of care?
Looking into the recent abstract presentations, could you please share with us thoughts regarding the upregulation of activation markers/ the transient loss of NK cells from peripheral blood/ migration of NK cells to the tumor?
Could you please tell us your thoughts regarding the BLA Denial and Withdrawal of Romidepsin, are there any parallels that could be drawn between that and AFM13 or AFM24?
How likely is it for AFM24 + Roche Atezolizumab 1PR (Gastric) or 1SD (Pancreatic) to become the preferred method of treatment, judging by the recent data?
The company has stated in the past that every patient overexpressing EGFR could be eligible for treatment with AFMD24 irrespective of mutational status. How would you rate that statement?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
